CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial


Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Please replace the graphic with the accompanying corrected graphic. The release reads: ARCTURUS REPORTS STRONG THREE-MONTH DURABILITY RESULTS FROM ARCT-154 BOOSTER…

Read More

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations


Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of Medicine Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™(tixagevimab and cilgavimab), formerly AZD7442, reduced…

Read More

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study


– Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study – Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals – Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON,…

Read More

Proof Diagnostics Submits Request For Emergency Use Authorization Seeking First Approval Of Crispr-based Molecular Point-of-care Covid-19 Test


If authorized by the FDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for COVID-19 (SARS-CoV-2) in as little as 18 minutes Excerpt from the Press Release: CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ — Proof Diagnostics, Inc., an innovative healthcare technology company delivering innovative solutions in molecular diagnostics, today announced the submission…

Read More

Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami


Transfer of Trial Sponsorship Final Major Milestone before Initiation of Lung Failure Pivotal Clinical Trial Excerpt from the Press Release: CEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated…

Read More

BioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19


BioFluidica LiquidScan Next-Generation Testing Platform, Can Detect Diseases in 15 Minutes Excerpt from the Press Release: SAN DIEGO, March 23, 2022 /PRNewswire/ — BioFluidica, a privately held biotechnology company, today announced they have been awarded a continuation grant from the Midwest Biomedical Accelerator Research Consortium (MBArC) on behalf of the National Institutes of Health Rapid Acceleration of…

Read More



Excerpt from the Press Release: DEL MAR, Calif,, March 23, 2022 /PRNewswire/ — Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. The current vaccines offer limited protection over time against the omicron variant that is now dominating…

Read More

Thermo Fisher Scientific to Support National Program to Accelerate SARS-CoV-2 Variant Identification


Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as…

Read More

Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron


CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates Neutralizing antibodies against Delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and…

Read More

Eiger’s Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study


Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron Eiger plans to submit data to FDA for Emergency Use Authorization (EUA) Management to host…

Read More